Lipoprotein(a) [Lp(a)]

Definition

Lipoprotein(a) is an LDL-like particle with a single apolipoprotein(a) [apo(a)] strand covalently bound to its ApoB-100 component. Unlike LDL, Lp(a) levels are predominantly genetically determined (~80–90% heritability) via the LPA gene, remain stable across the lifespan, and are only minimally modified by lifestyle. Lp(a) is a causal risk factor for ASCVD and calcific aortic valve disease, with risk increasing continuously at higher concentrations across all ancestries.

Key Concepts

Structure and Assembly

• Lp(a) = LDL-like lipid core + apoB100 + apolipoprotein(a) [apo(a)] linked via a single disulfide bond sources/lpa-aha-2021 (very high)
• Apo(a) contains 10 kringle IV (KIV) subtypes; KIV type 2 is present in variable copy numbers (1 to >40) → highly variable molecular mass (300–800 kDa); >80% of individuals carry 2 different-sized isoforms; small isoforms → higher Lp(a) levels (higher molar production rate) (sources/lpa-jacc-2017 — high)
• Assembly: 2-step process — (1) noncovalent lysine-dependent interaction between apo(a) KIV and the N-terminal domain of apoB, followed by (2) extracellular covalent disulfide bond formation at KIV-9 of apo(a) and apoB sources/lpa-aha-2021 (very high)
• LPA gene evolved by duplication of the plasminogen (PLG) gene — explains structural homology and proposed antifibrinolytic properties; species distribution limited to humans, Old World monkeys, apes, and hedgehogs (limits animal model research) sources/lpa-aha-2021 (very high)
• Apo(a) has no enzyme activity and no lipid transport function; contains lysine-binding sites enabling accumulation in arterial endothelium and aortic valve leaflets; these properties concentrate atherogenicity in a spatially targeted way (sources/lpa-jacc-2017 — high)
• Smaller apo(a) isoforms (fewer KIV2 repeats, higher Lp(a) levels) have: (1) increased OxPL-binding capacity; (2) greater lysine-binding to fibrin and vessel walls; (3) greater plasmin inhibition → more thrombogenic; (4) synergistic action with small-dense LDL and OxLDL — isoform size contributes risk beyond Lp(a) mass level alone (sources/lpa-molecules-2023 — medium)
• Arterial wall retention mechanism: Lp(a) binds proteoglycan decorin via a 2-part interaction — apoB-100 electrostatic bond to the GAG chain + apo(a) hydrophobic bond to decorin's protein core; the second interaction explains greater arterial wall affinity vs LDL; alpha-defensins (neutrophil-derived) cluster with Lp(a) extracellularly, preventing endothelial traversal and maintaining subintimal retention (sources/lpa-molecules-2023 — medium)
• Liver is the primary site of Lp(a) catabolism; clearance receptors not definitively identified (LDL-R, SR-B1, LRP1, LRP8 implicated); LDLR plays only a modest role — statins upregulate LDLR but do not reliably lower Lp(a); Lp(a) has longer residence time than LDL because apo(a) near LDLR binding site of apoB interferes with docking (sources/lpa-jacc-2017 — high; sources/lpa-aha-2021 — very high)

Epidemiology and Genetics

• Population distribution is highly skewed, highest levels in individuals of African or South Asian ancestry sources/lipid-aha-2026 (very high)
• Mean/median Lp(a) approximately 7–20 mg/dL (20 nmol/L) in general population; ~20% of population has levels ≥50 mg/dL (125 nmol/L) = "elevated"
• Inherited with autosomal codominant transmission; genetic testing for LPA not advised for clinical purposes — measured Lp(a) concentration is sufficient
• Lp(a) concentration determined by number of kringle IV-type 2 (KIV-2) repeats in apo(a); inverse relationship — more repeats → smaller isoform → lower Lp(a) in most assays (mass-based)
• KIV2 copy number variant accounts for 19–69% of interindividual heterogeneity; additional LPA SNPs explain further variation sources/lpa-aha-2021 (very high)
• APOE ε2 allele associated with lower Lp(a) levels (~0.5% of variation); APOH (β2-glycoprotein 1, which binds apo(a) KIV2) also implicated sources/lpa-aha-2021 (very high)
• Intraindividual biological variability up to 20% — consider averaging 2 measurements for borderline-risk individuals before making treatment decisions sources/lpa-aha-2021 (very high)

Risk Quantification

• Prospective studies show robust associations with nonfatal ASCVD, aortic valve disease, CVD, and all-cause mortality sources/lipid-aha-2026 (very high)
• Risk is independent of LDL-C and other risk factors, even at low LDL-C
• Relative risk compared with population median (~7 mg/dL / 20 nmol/L):

• CardiogramPlus4D (63,746 CAD cases + 130,681 controls): the LPA locus is numerically the most potent genetic association with CAD — more potent than LDL-related, PCSK9, and 9p21 variants; this remains underappreciated (sources/lpa-jacc-2017 — high)
• Meta-analysis (126,634 participants; 1.3 million person-years): curvilinear risk accelerating at >24 mg/dL; genetic (Mendelian randomization) studies show linear risk with OR up to 4 for highest vs lowest Lp(a) (sources/lpa-jacc-2017 — high)
• Bruneck Study (n=826; 15-yr follow-up; intermediate-risk community subjects): adding Lp(a) to Framingham/Reynolds risk scores reclassified 39.6% of individuals into higher or lower risk categories — strongest reclassification data for any single biomarker in intermediate-risk patients (sources/lpa-jacc-2017 — high)
• Risk derived from UK Biobank (Patel et al, n=460,000); HR 1.11 per 50 nmol/L increment (95% CI 1.10–1.12), log-linear above median, similar across ancestry groups sources/lpa-aha-2021 (very high)
• Practical risk-adjustment formula (validated with PCE framework, predates PREVENT):
  Updated 10-y risk = PCE risk × 1.11^(Lp(a) nmol/L ÷ 50)
  Example: PCE 10% + Lp(a) 250 nmol/L → 10% × 1.11^5 = 16.9% sources/lpa-aha-2021 (very high)
• Residual risk despite controlled LDL-C (Tsimikas pooled analysis):
  • AIM-HIGH: LDL-C 65.2 mg/dL + Lp(a) >125 nmol/L (~50 mg/dL; ≥75th %ile) → 89% higher MACE vs same LDL-C with low Lp(a) (sources/lpa-jacc-2017 — high)
  • JUPITER: LDL-C 55 mg/dL + Lp(a) >54 nmol/L (~21 mg/dL) → 71% higher MACE (sources/lpa-jacc-2017 — high)
  • LIPID: LDL-C ~112 mg/dL + Lp(a) >73.7 mg/dL → 23% higher MACE (sources/lpa-jacc-2017 — high)
  • Pooled (13,167 statin-treated patients): weighted HR 1.61 (mean LDL-C 89.1 mg/dL, mean Lp(a) 54.9 mg/dL) — Lp(a) remains an independent risk factor even with well-controlled LDL-C (sources/lpa-jacc-2017 — high)
• Women's Health Study: women with elevated Lp(a) were the only subgroup to derive benefit from aspirin in this primary prevention trial — suggests antiplatelet therapy may attenuate Lp(a)-mediated arterial risk (sources/lpa-jacc-2017 — high)
• Racial hierarchy (Tsimikas): African descent > South Asian > Caucasian > Hispanic > East Asian; ARIC (3,467 Black + 9,851 White; 20-yr follow-up): Lp(a) positively and similarly associated with CVD events in both groups — elevated Lp(a) is an independent risk factor in all groups (sources/lpa-jacc-2017 — high)
• Stroke: causal role for Lp(a) weaker than for CHD/CAVD; Mendelian randomization data show ~13% lower stroke risk per 1 SD lower genetically determined Lp(a) vs ~30–40% lower risk for CHD/PAD/CAVD sources/lpa-aha-2021 (very high)
• Venous thromboembolism: genetic data do not support a meaningful VTE–Lp(a) association except at very high levels; apo(a) antifibrinolytic properties in vitro likely masked when covalently bound to apoB in the Lp(a) particle sources/lpa-aha-2021 (very high); LPA SNPs also not associated with VTE in clinical thrombosis studies — elevated Lp(a) is primarily an atherosclerosis risk (sources/lpa-jacc-2017 — high)
• Relative risk from Lp(a) is multiplicative with other cardiovascular risk factors — elevated Lp(a) + additional risk factors = compounded risk

Measurement and Assay Standardisation

• Historical dual-unit problem: Lp(a) has long been measured in two incompatible units — mg/dL (total Lp(a) mass, assumes constant component proportions — scientifically invalid given apo(a) size variability) and nmol/L (molar concentration of apo(a) particles — preferred, isoform-insensitive) sources/lpa-aha-2021 (very high)
• Gold-standard assay: isoform-insensitive ELISA calibrated in nmol/L, traceable to WHO/IFCC Reference Material SRM-2B; multiple guidelines now mandate nmol/L reporting sources/lpa-aha-2021 (very high)
• No unbiased conversion factor from mg/dL to nmol/L — do not convert between units; results from differently calibrated assays are not directly comparable
• A mass spectrometry candidate reference method has been validated with high concordance to the gold-standard ELISA sources/lpa-aha-2021 (very high)
• COR 1: Measure at least once in all adults for ASCVD risk assessment sources/lipid-aha-2026 (very high)
• COR 1: Cascade testing of first-degree family members if FH, premature ASCVD, or high Lp(a)
• COR 1: Use assays insensitive to apo(a) isoform size and traceable to official reference standard materials
• Reported in either nmol/L (molar) or mg/dL (mass); molar units preferred — isoform-insensitive
• Fasting NOT required for Lp(a) testing
• Single measurement generally sufficient; stable except in menopause transition, kidney/liver/thyroid disease, pregnancy, or certain medications
• Secondary causes of elevated Lp(a): kidney disease, liver disease, thyroid disease, pregnancy, menopause, some medications (inflammation may increase or decrease)

Clinical Significance as Risk Enhancer

• Lp(a) ≥125 nmol/L (50 mg/dL) classified as a risk enhancer in primary prevention sources/lipid-aha-2026 (very high)
• Should trigger more intensive management of all modifiable cardiovascular risk factors
• At ≥430 nmol/L: risk equivalent to HeFH — warrants very aggressive ASCVD risk reduction
• Lp(a) is additive to LDL-C, hsCRP, and conventional risk factors; in Women's Health Study, 20-year HR for MACE: hsCRP top quintile 1.70, LDL-C top quintile 1.35, Lp(a) top quintile 1.33

Vascular Inflammation and Endothelial Dysfunction Mechanisms

• Adhesion molecule upregulation: Lp(a) upregulates VCAM-1 and E-selectin on coronary endothelial cells; upregulates ICAM-1 on HUVECs (partly via TGF-β inhibition); Mac-1 (β2-integrin) + Lp(a) → monocyte attachment via NF-κB activation; MCP-1 induction (direct OxPL binding + indirect production) (sources/lpa-molecules-2023 — medium)
• OxPL bidirectional dose effect: At low Lp(a) concentrations, Lp-PLA2 on Lp(a) removes OxPLs from plasma (anti-inflammatory); at high Lp(a), OxPLs on apo(a) compete for the Lp-PLA2 catalytic site → autocrine loop amplifying OxPL accumulation in arterial wall. This dose-dependence may partly explain the curvilinear risk profile (sources/lpa-molecules-2023 — medium)
• Endothelial barrier disruption: Lp(a) accelerates endothelial cell senescence (ROS; p53/p21 upregulation); ROS disrupts monolayer permeability; apo(a) activates Rho/ROCK pathway → myosin light chain phosphorylation → actin cytoskeleton rearrangement → endothelial cell contraction → loss of cell contact (sources/lpa-molecules-2023 — medium)
• EPC impairment: Apo(a) attenuates endothelial progenitor cell adhesion and migration; reduces CD31+ capillary formation; anti-angiogenic — full-length and urinary apo(a) fragments halt capillary tube generation in vitro (sources/lpa-molecules-2023 — medium)
• Flow-mediated dilation: Lp(a) inversely correlated with FMD (r = −0.33, p<0.005); small apo(a) isoforms ≤22 KIV repeats → significantly lower FMD independent of Lp(a) concentration — isoform size exerts endothelial effects beyond Lp(a) mass (sources/lpa-molecules-2023 — medium)
• MMP-mediated plaque destabilization: MMP-12 cleaves Lp(a) → F1 and F2 fragments; F2 interacts with fibrinogen, fibronectin, decorin; Lp(a)-driven IL-8 downregulates TIMPs → further MMP-mediated ECM degradation; OxPL-apo(a) drives ER-stressed macrophage apoptosis → plaque necrosis (sources/lpa-molecules-2023 — medium)
• Neointimal hyperplasia: Lp(a) is a predictor of vein graft stenosis and PTCA restenosis; mechanism — Mac-1-mediated monocyte infiltration + VSMC proliferation via TGF-β suppression (plasmin-plasminogen pathway blockade) (sources/lpa-molecules-2023 — medium)

Thrombogenicity Mechanisms

• Platelet GPIIb/IIIa activation: Apo(a) contains an RGD (Arg-Gly-Asp) epitope that binds GPIIb/IIIa on platelets → platelet activation and aggregation via cAMP-dependent mechanism; this pathway is distinct from apo(a) lysine-binding sites (sources/lpa-molecules-2023 — medium)
• Tissue Factor upregulation: Lp(a) upregulates TF expression on monocytes via αMβ2 (Mac-1)/NF-κB pathway; simultaneously, Lp(a) binds and inhibits TFPI in a lysine-dependent manner — dual amplification of extrinsic coagulation cascade (sources/lpa-molecules-2023 — medium)
• Fibrinolysis inhibition: Apo(a) competes with plasminogen for lysine-binding sites on fibrin surface → quaternary complex formation → reduced tPA turnover; PAI-1 upregulation; fibrin clot tightening demonstrated (Lp(a) ≥30 mg/dL → lower clot permeability); these mechanisms are additive to plasmin competition (sources/lpa-molecules-2023 — medium)
• VTE risk context: Elevated Lp(a) (≥30 mg/dL) found in 20% of VTE patients vs 7% controls; FV G1691A (Factor V Leiden) + elevated Lp(a) synergistically increase VTE prevalence — thrombotic risk amplified when combined with underlying coagulation propensity; independent causal VTE link without cofactor not established (sources/lpa-molecules-2023 — medium)

Management of Elevated Lp(a)

Step 1 — Optimize modifiable risk factors (COR 1):

• Intensive control of LDL-C, blood pressure, glycaemia
• Smoking cessation, healthful diet, physical activity (AHA Life's Essential 8)
• Observational data: lifestyle alignment associated with 67% lower ASCVD risk among those with elevated Lp(a) sources/lipid-aha-2026 (very high)

Step 2 — Intensify LDL-C lowering:

• Statins: do NOT specifically lower Lp(a); ESC 2025 (citing 7 placebo-controlled RCTs) states no effect on Lp(a) sources/lipid-esc-2025 (very high) — CONTESTED by individual-patient-level analysis of 3,896 patients showing mean +11% Lp(a) increase (up to +50% in some studies) and +24% OxPL-apoB increase (sources/lpa-jacc-2017 — high); see Contradictions section
• High-intensity statin: still provides ~30–40% RRR in events among those with elevated Lp(a) (JUPITER trial: on-treatment LDL-C 54 mg/dL); statin benefit not negated by modest Lp(a) increase

Step 3 — Add PCSK9 inhibitor (for ASCVD + elevated Lp(a)):

• In ASCVD + elevated Lp(a) not at LDL-C/non-HDL-C goals on max statin → add PCSK9 mAb (COR 1) sources/lipid-aha-2026 (very high)
• PCSK9 mAbs (evolocumab, alirocumab) lower Lp(a) by ~15–30% (not FDA-approved specifically for Lp(a))
• Post hoc FOURIER and prespecified ODYSSEY Outcomes analyses: patients with higher Lp(a) derive greater benefit; Lp(a) lowering may have contributed to event reduction
• Alirocumab ODYSSEY pooled analysis: Lp(a) reduction only associated with CV event reduction in those with Lp(a) ≥50 mg/dL

Emerging therapies (investigational):

• mRNA-targeting therapies (antisense oligonucleotides, siRNA): dramatically lower Lp(a) by >80%; currently in phase 3 cardiovascular outcomes trials
• >50% Lp(a) reduction likely required for clinical benefit: CETP inhibitors (20–30% reduction) and niacin (19–39% reduction) failed to show CV event benefit; this threshold hypothesis supports the rationale for GalNAc-ASO/siRNA approaches achieving 80–99% reduction (sources/lpa-jacc-2017 — high)
• OxPL-apoB as parallel biomarker: OxPL-apoB (primarily reflects Lp(a) OxPL content) is a similar or superior predictor to Lp(a) mass for CVD and CAVS diagnosis/prognosis; reduction in OxPL-apoB alongside Lp(a) is a key efficacy marker for ASO therapies (sources/lpa-jacc-2017 — high)
• Oral small-molecule inhibitors of Lp(a) production also in development
• Lipoprotein apheresis: FDA-approved for Lp(a) ≥60 mg/dL + FH + CAD/PAD (observational basis only); time-averaged reduction 30–35%; Germany/UK reimburse at >60 mg/dL + recurrent CVD
• Aspirin: Women's Health Study — women with elevated Lp(a) were the only subgroup to benefit from aspirin; suggests antiplatelet therapy may attenuate Lp(a)-mediated risk (post hoc; prospective trials needed) (sources/lpa-jacc-2017 — high)
• CETP inhibitors (obicetrapib): BROADWAY trial (NEJM 2025; n=2,530) showed obicetrapib reduces Lp(a) by 33.5% (IQR −36.9 to −30.2) on top of maximum lipid-lowering therapy — notably, CETP inhibitors lower Lp(a) in contrast to statins. Patients were not selected for elevated Lp(a); effect in high-baseline-Lp(a) subgroup not yet characterised; 33.5% reduction may be below the >50% threshold for clinical benefit sources/obicetrapib-broadway-nejm-2025 (high)

ESC 2025: Lp(a) as CV Risk-Enhancing Factor

• COR IIa B (new ESC 2025 recommendation): Lp(a) levels above 50 mg/dL (105 nmol/L) should be considered in all adults as a CV risk-enhancing factor, with higher Lp(a) levels associated with greater increase in risk sources/lipid-esc-2025 (very high)
• ESC 2025 threshold for risk modifier: >50 mg/dL (>105 nmol/L) — defined as affecting at least 20% of the population
• ESC 2025 specifically designates Lp(a) >105 nmol/L as a risk modifier to potentially reclassify moderate-risk individuals or those around treatment decision thresholds to higher category (Box 1)
• ESC 2025 confirms statins have no effect on Lp(a) concentrations (individual-level data from 7 placebo-controlled statin trials); clinical decision-making should not be affected by this — patients with high Lp(a) should still take high-intensity statins if risk is sufficiently high
• ESC 2025 on emerging RNA therapies: ASO/siRNA targeting apo(a) production → 80–98% Lp(a) reduction; oral small-molecule inhibitors also in development; phase 3 CVOTs ongoing

Contradictions / Open Questions

• No dedicated cardiovascular outcomes trial has shown that specifically lowering Lp(a) reduces ASCVD events — all existing data are post hoc or from mechanistic studies; phase 3 RCTs with Lp(a)-specific agents (olpasiran, pelacarsen, zerlasiran) are ongoing
• Optimal Lp(a) treatment threshold remains uncertain: current COR 1 recommendation to lower LDL-C more if ASCVD + elevated Lp(a), but whether specific Lp(a)-lowering is warranted at 125–249 nmol/L vs ≥250 nmol/L vs ≥430 nmol/L is unclear
• Interassay variability: nmol/L-to-mg/dL conversion is approximate (~2.5×); comparison of results between laboratories remains unreliable without standardization
• ESC vs ACC/AHA Lp(a) threshold discrepancy: ESC 2025 designates Lp(a) >50 mg/dL (>105 nmol/L) as risk-enhancing; ACC/AHA 2026 uses ≥125 nmol/L (≥50 mg/dL) as risk enhancer — the same mass threshold but the molar threshold differs (ESC 105 nmol/L vs ACC/AHA 125 nmol/L). The discrepancy (~20 nmol/L) arises from differences in reference populations and conversion approximations. This means patients with Lp(a) 105–124 nmol/L are considered elevated by ESC but not yet by ACC/AHA sources/lipid-esc-2025 sources/lipid-aha-2026 (both very high)
• Statin effect on Lp(a) — DIRECT CONTRADICTION: ESC 2025 (citing 7 placebo-controlled statin RCTs) states statins have no effect on Lp(a) sources/lipid-esc-2025 (very high). Tsimikas 2017 JACC (individual-level analysis of 3,896 patients across 5 statins) reports a mean +11% Lp(a) increase (up to +50% in some studies) and +24% OxPL-apoB increase (sources/lpa-jacc-2017 — high). The discrepancy likely reflects: (1) RCT mean-level analyses mask within-patient changes; (2) baseline Lp(a) distribution — patients with high Lp(a) may show larger absolute increases. Clinical implication: statin benefit clearly outweighs any Lp(a) signal, but the possibility of statin-induced Lp(a) elevation in high-baseline patients warrants awareness
• Minimum effective Lp(a)-lowering threshold unestablished: Tsimikas proposes >50% reduction is necessary for clinical benefit based on CETP inhibitor/niacin failures at 20–30%. This is mechanistically plausible but unproven — HORIZON (olpasiran ~90% reduction) and Lp(a) HORIZON (pelacarsen ~80% reduction) CVOTs will provide the first direct test (sources/lpa-jacc-2017 — high)

Lp(a) in Calcific Aortic Valve Disease (CAVD)

• Lp(a) has an independent causal role in CAVD initiation (Mendelian randomization), distinct from and additive to LDL-C sources/vhd-mechanism-aha-2024 (very high)
• Mechanism: covalently linked oxidised phospholipids on Lp(a) → activate osteogenic transcriptional programs in valve interstitial cells (VICs) → fibrocalcific transformation
• Autotaxin (ATX): enzyme metabolising Lp(a)-associated lysophosphatidylcholine; ATX gene expression elevated in CAVD VICs; associated with circulating Lp(a); autotaxin overexpression promotes valve mineralisation in murine models sources/vhd-mechanism-aha-2024 (very high)
• Lp(a) is associated with CAVD onset but NOT with progression of established aortic valve calcification — important therapeutic window implication; early Lp(a) lowering may be necessary before calcification is established
• ASTRONOMER Trial (rosuvastatin in mild-moderate AS): elevated Lp(a) >58.5 mg/dL AND OxPL-apoB >5.5 nM (3rd tertile) → AV jet velocity progression 0.26 vs 0.17 m/s/year vs lowest tertile; AVR required in 20.4%; younger patients (<57 yr) had nearly double the progression rate; rosuvastatin raised Lp(a) +20% and OxPL-apoB +46% and did not reduce AS progression — consistent with Lp(a) as primary driver of genetic CAVS (sources/lpa-jacc-2017 — high)
• Autotaxin case-control (n=150 CAVS+CAD vs 150 CAD): autotaxin + Lp(a) >50 mg/dL → OR 3.46 for CAVS; autotaxin + OxPL-apoB → OR 5.48 for CAVS — autotaxin synergizes with Lp(a) OxPL to drive valve calcification (sources/lpa-jacc-2017 — high)
• LPA SNP rs10455872 identified as the only monogenic risk factor for aortic valve calcification across multiple racial groups in GWAS of >2.5 million SNPs (sources/lpa-jacc-2017 — high)
• Pelacarsen (anti-sense oligonucleotide targeting LPA): active phase 2/3 trial targeting AS progression (NCT05646381, n=502); primary endpoints — aortic valve calcium score + peak AV velocity; will be first RCT to test Lp(a)-specific lowering in AS sources/vhd-mechanism-aha-2024 (very high)
• See concepts/CAVD-Mechanisms for full CAVD molecular pathway

Connections

• Related to concepts/Dyslipidemia-Management — Lp(a) measurement and management are integrated into the overall lipid guideline
• Related to concepts/ASCVD-Risk-Assessment — Lp(a) ≥125 nmol/L is a key risk enhancer in CPR Framework
• Related to concepts/Familial-Hypercholesterolemia — elevated Lp(a) is common in FH (ascertainment bias); doubles risk on top of FH
• Related to concepts/CAVD-Mechanisms — Lp(a) as causal driver of CAVD initiation via oxidised phospholipids and autotaxin

Sources

• sources/lipid-aha-2026
• sources/lipid-esc-2025
• sources/lpa-aha-2021
• sources/vhd-mechanism-aha-2024
• sources/obicetrapib-broadway-nejm-2025 — BROADWAY RCT; CETP inhibitor lowers Lp(a) −33.5%
• sources/lpa-jacc-2017 — Tsimikas 2017 JACC: structure/mechanisms, 9 controversies, ASTRONOMER data, AIM-HIGH/JUPITER/LIPID HR quantification, statin effect analysis (3,896 pts), >50% reduction threshold hypothesis, IONIS-APO(a)-LRx
• sources/lpa-molecules-2023 — Lampsas et al. 2023 Molecules: detailed thrombogenicity mechanisms (GPIIb/IIIa RGD; TF/TFPI; PAI-1; fibrin competition); endothelial dysfunction (Rho/ROCK; EPC impairment; FMD data); decorin 2-part binding; smaller isoform effects; neointimal hyperplasia; treatment review (niacin only approved option; PCSK9i 26.7% pooled data)